Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.

Guzauskas GF, Masaquel A, Reyes C, Bernaards C, Krivasi T, Veenstra DL

J Med Econ, 21(10):960-967, 06 Jul 2018

Cited by: 2 articles | PMID: 29898619

Cost-effectiveness of rituximab in follicular lymphoma.

Johnston KM, Bolbocean C, Connors J, Peacock S

Expert Rev Pharmacoecon Outcomes Res, 12(5):569-577, 01 Oct 2012

Cited by: 4 articles | PMID: 23140274

Review

Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.

Haukaas FS, Ohna A, Krivasi T

Appl Health Econ Health Policy, 16(4):569-577, 01 Aug 2018

Cited by: 1 article | PMID: 29923173

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.

Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, [...] Salles G

Lancet Oncol, 19(4):549-561, 20 Feb 2018

Cited by: 92 articles | PMID: 29475724 | PMCID: PMC5882539